Abstracts Archive - Page 2025 of 2607 - ACR Meeting Abstracts

Abstract Number: 2316 • 2015 ACR/ARHP Annual Meeting
An Ethnographic Observational Study of the Biologic Initiation Conversation Between Rheumatologists and Biologic Naïve Rheumatoid Arthritis Patients
Nicholas Kottak¹, Melissa Rosenberg², Dennis Parenti³ and Shelly Kafka³, ¹Ethnographic Solutions, Washington, DC, ²Janssen Pharmaceuticals Inc, Horsham, PA, ³Janssen Scientific Affairs, LLC, Horsham, PA
Background/Purpose: To better understand how rheumatologists communicate the need to initiate biologic treatment and explain the risks and benefits, Janssen Pharmaceuticals initiated an ethnographic market…
Abstract Number: 2317 • 2015 ACR/ARHP Annual Meeting
Different Rheumatoid Arthritis Disease Activity Measures Often Provide Discordant Results in Clinical Practice Populations
Gary Crump¹, James Bower², Terrence Foley³, J. Timothy Harrington², Nikita Hegde⁴, Drew Johnson⁵, Rafia Khalil⁶, Edmund LaCour⁷ and Robert Perhala⁸, ¹Rheumatology Associates - Louisville, Louisville, KY, ²Joiner Associates LLC, Madison, WI, ³Terrence Foley MD Inc, Concord Twp, OH, ⁴Akron General Hospital, Cuyahoga Falls, OH, ⁵Crescendo Bioscience, Inc., South San Francisco, CA, ⁶Rafia Khalil Arthritis & Rheumatology Center, PC, Port Huron, MI, ⁷Dothan Medical Associates PC, Dothan, AL, ⁸University Hospitals, Cleveland, OH
Background/Purpose: Accurate rheumatoid arthritis (RA) disease activity assessment is required for treatment consistent with Treat-to-Target (T2T) recommendations. Rheumatologists currently use a variety of patient-generated, physician-generated,…
Abstract Number: 2318 • 2015 ACR/ARHP Annual Meeting
Inflammatory Arthritis Patient Perspectives on Strategies to Support Medication Adherence: A Qualitative Study Using a Novel Group Exercise
Sharan K. Rai¹, Pavandeep Mehat², Anne Townsend³, Carlo Marra⁴, Harpreet Chhina⁵, Rhonda Shuckett⁶ and Mary A. De Vera², ¹Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, ²Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ³Medical School, University of Exeter, Exeter, United Kingdom, ⁴School of Pharmacy, Memorial University, St. John's, NF, Canada, ⁵Orthopedic Surgery, BC Children's Hospital, Vancouver, BC, Canada, ⁶Rheumatology, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Disappointing and inconsistent findings of adherence intervention research in inflammatory arthritis (IA) highlight the need for further work in designing interventions that promote and…
Abstract Number: 2319 • 2015 ACR/ARHP Annual Meeting
Mobile Medical Documentation of Patient-Reported-Outcome
Jutta G. Richter¹, Christina Kampling¹, Gamal Chehab¹, Hasan Acar¹, Arnd Becker², Meike Dieckert¹ and Matthias Schneider¹, ¹Policlinic of Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ²Ortenau Klinikum Offenburg-Gengenbach, Gengenbach, Gengenbach, Germany
Background/Purpose: Mobile medical Applications (mApps) with integrated patient-reported outcome instruments (PROs) allow patients (pts) with rheumatoid arthritis (RA) self-monitoring and might strengthen self-management. Use of…
Abstract Number: 2320 • 2015 ACR/ARHP Annual Meeting
The Use of Doppler Ultrasound in Patients with Rheumatoid Arthritis Improves Patient Understanding of Disease and Adherence to Treatment and Alters Clinical Practice
Fred Joshua¹, Christine Bailey², Mona Marabani³, Evange Romas⁴, Raymond White³ and Peter Wong⁵, ¹Combined Rheumatology Practice and Macquarie University, Sydney, Australia, ²AbbVie, Sydney, Australia, ³Private Rheumatology Practice, Sydney, Australia, ⁴Department of Medicine, University of Melbourne, Melbourne, Australia, ⁵Mid-North Coast Arthritis Clinic and University of New South Wales Rural Clinical School, Coffs Harbour, Australia
Background/Purpose: Doppler ultrasound (DUS) can detect subclinical joint inflammation and can be used to predict disease relapse or flare in patients with RA. The objectives…
Abstract Number: 2321 • 2015 ACR/ARHP Annual Meeting
Performance of Patient Reported Outcomes in the Assessment of Rheumatoid Arthritis Disease Activity: The Experience of the Espoir Cohort
Hélène Che¹, Bernard Combe², Jacques Morel³, Alain G. Cantagrel⁴, Laure Gossec⁵ and Cédric Lukas⁶, ¹Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ²Rheumatology, Hopital Lapeyronie, Montpellier, France, ³Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ⁴Rheumatology, INSERM CNRS UMR 1043, Paul Sabatier University Toulouse, Purpan Teaching Hospital, Toulouse, France, ⁵Rheumatology, Pitié Salpetriere Hospital, Paris, France, ⁶Hopital Lapeyronie, Montpellier, France
Background/Purpose: Activity of rheumatoid arthritis (RA) can be assessed by several outcome measures : joint counts, inflammatory syndrom but also auto-questionnaires such as global patient…
Abstract Number: 2323 • 2015 ACR/ARHP Annual Meeting
Patient Priorities in Rheumatoid Arthritis (RA) Research: An Exploration of Patient Perspectives from Those Enrolled in an Ontario RA Cohort
Laura Fullerton¹, Angela Cesta², Catherine Hoffstetter³ and Claire Bombardier^2,4,5, ¹Support, Systems and Outcomes, University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ³Patient partner, Toronto, ON, Canada, ⁴Division of Rheumatology and Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, ⁵Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Patient experiences with rheumatoid arthritis (RA) symptoms, treatments, and rheumatology care are critically important for the assessment of treatment-effectiveness and quality of care for…
Abstract Number: 2324 • 2015 ACR/ARHP Annual Meeting
Understanding the Importance of a Patient’s Role in the Management of RA: Results from a Patient-Based Survey
Ara Dikranian¹, James Galloway², Jörn Kekow³, Anna Maniccia⁴, Dean Spurden⁵, Eustratios Bananis⁶, Allan Gibofsky⁷ and for the RA NarRAtives advisory panel, ¹San Diego Arthritis Medical Clinic, San Diego, CA, ²Academic Department of Rheumatology, King´s College London, London, United Kingdom, ³University of Magdeburg, Magdeburg, Germany, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Tadworth, United Kingdom, ⁶Pfizer Inc, Collegeville, PA, ⁷Weill Cornell Medical College and Hospital for Special Surgery, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, debilitating condition for which there is no cure. The RA NarRAtive is a global initiative to identify patient…
Abstract Number: 2325 • 2015 ACR/ARHP Annual Meeting
Quantitative Clues to Recognize and Document Comorbid Fibromyalgia in Routine Care of Patients with Other Rheumatic Diagnoses on a 10 Cm Distress Visual Analog Scale Found on 1-Page Physician Rheumetric Checklist
Kathryn A. Gibson¹, Katherine J. Bryant² and Theodore Pincus³, ¹Liverpool Hospital, Liverpool, Australia, ²University of New South Wales, Sydney, Australia, ³Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: A physician global estimate (DOCGL) is commonly used to assess patients with rheumatic diseases. Fibromyalgia (FM) has been reported as a comorbidity in 10-35%…
Abstract Number: 2326 • 2015 ACR/ARHP Annual Meeting
Patient Preferences Regarding Route of Biologic Administration in an Inflammatory Arthritis Cohort
Alysia Kwiatkowski¹, Lucas Grisanti², Joseph Grisanti³ and James Hatem⁴, ¹Internal Medicine, Albany Medical Center, Albany, NY, ²Department of Biology, College of Wooster, Wooster, OH, ³Buffalo Rheumatology and Medicine, Orchard Park, NY, ⁴BioStatistics, Buffalo Rheumatology and Medicine, Orchard Park, NY
Background/Purpose: Multiple biologic treatment modalities are available for managing systemic inflammatory disease states. Patient preference regarding routes of administration is frequently unclear and has not…
Abstract Number: 2327 • 2015 ACR/ARHP Annual Meeting
Documentation of Clinical Improvement in Patient with Polymyalgia Rheumatica According to MDHAQ/RAPID3 (Multidimensional Health Assessment Questionnaire/Routine Assessment of Patient Index Data): Longitudinal Analysis from Routine Care
Isabel Castrejón¹, Annie Huang¹, Sarah L. Everakes², Ailda Nika¹, Winston Sequeira¹ and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Internal Medicine, Rush University Medical Center, Chicago, IL
Background/Purpose: RAPID3 is an index found on the MDHAQ, which is effective in rheumatoid arthritis (RA) clinical trials and clinical care (1). MDHAQ/RAPID3 also is…
Abstract Number: 2328 • 2015 ACR/ARHP Annual Meeting
The Correlation of Childhood Health Assessment Questionnaire with Disease Activity in Juvenile Idiopathic Arthritis
Watchareewan Sontichai^1,2 and Soamarat Vilaiyuk¹, ¹Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, ²Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a common childhood arthritis, which is classified into 7 subtypes. Each subtype has different clinical manifestations, treatment, and disease…
Abstract Number: 2329 • 2015 ACR/ARHP Annual Meeting
Describe Treatments As ‘new’ or ‘old’ at Your Peril: Influences on Patient Decision Making
Mark Harrison^1,2, Carlo Marra³ and Nick Bansback^4,5, ¹Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, ²Centre for Health Evaluation and Outcomes Sciences, St Paul's Hospital, Vancouver, BC, Canada, ³School of Pharmacy, Memorial University, St John's, NF, Canada, ⁴St. Paul's Hospital, Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ⁵School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Using an example of a new drug for rheumatoid arthritis which offers comparable effectiveness and side-effect point estimates to older drugs, we explore preferences…
Abstract Number: 2330 • 2015 ACR/ARHP Annual Meeting
The Turkish Validity and Reliability of the Systemic Lupus Erythematosus Quality of Life Questionnaire (L-QoL)
M Tuncay Duruoz¹, Canan Sanal Top², Ilhan Sezer³, Figen Yılmaz⁴, Cagri Ünal², Hatica Sule Baklacioglu⁵, Firat Ulutatar⁶ and Pamir Atagunduz⁷, ¹Dept of PM&R, Rheumatology Clinic, Marmara University Medical School, Istanbul, Turkey, ²PM&R, Marmara University Medical School, Istanbul, Turkey, ³Rheumatology, Physical Medicine and Rheabilitation, Antalya Education and Research Hospital, Antalya, Turkey, ⁴PM&R, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey, ⁵Rheumatology, Marmara University Medical School, Istanbul, Turkey, ⁶Physical Medicine and Rehabilitation Department, Marmara University Medical School, Istanbul, Turkey, ⁷Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey
Background/Purpose: The Systemic Lupus Erythematosus Quality of Life Questionnaire (L-QoL) is a disease-specific measure of needs-based quality of life developed in the United Kingdom (1).…
Abstract Number: 2331 • 2015 ACR/ARHP Annual Meeting
Agreement Between Patient’s and Physician’s Reported Bath Ankylosing Spondylitis Disease Activity Index in Patients with Axial Spondyloarthritis
Liana Ghukasyan¹, Adrien Etcheto², Anna Moltó³ and Maxime Dougados³, ¹Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, ²Rheumatology B, Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, ³Paris Descartes University, Rheumatology Department, Cochin Hospital, AP-HP. INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France
Background/Purpose : The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is the more frequently used index for evaluating disease activity in Spondyloarthritis (SpA) in clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].